DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)Business Wire • 01/23/23
This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to RunThe Motley Fool • 01/18/23
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICAREBusiness Wire • 01/10/23
DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)Business Wire • 01/05/23
DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection TestBusiness Wire • 11/15/22
DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA CongressBusiness Wire • 10/10/22
DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern CaliforniaBusiness Wire • 10/03/22
DermTech, Inc. (DMTK) CEO John Dobak on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 OutlookBusiness Wire • 08/08/22
Earnings Preview: DermTech, Inc. (DMTK) Q2 Earnings Expected to DeclineZacks Investment Research • 08/01/22
DermTech Appoints Chief Compliance Officer and SVP of Research and DevelopmentBusiness Wire • 07/28/22
DermTech Joins PeDRA Corporate Council, Supporting Efforts to Address Pediatric Skin DiseasesBusiness Wire • 07/06/22